Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of PL-5 spray for secondary wound infection
ChiCTR2100047202Phase 3Recruiting
- Sponsor
- Shenzhen Second People's Hospital
- Start
- Jul 2021
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3 trial of peceleganan in Wound infection (WI) (2 arms), sponsored by Shenzhen Second People's Hospital. Primary endpoint: Clinical efficacy on day 1 after the final administration. Started Jul 2021; status: recruiting.
02
Drugs
peceleganan
03
Conditions
Wound infection (WI)
Beyond the preview
Go deeper on ChiCTR2100047202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047202.